Equities

Daito Pharmaceutical Co Ltd

Daito Pharmaceutical Co Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of May 31 2024202420232022
ASSETS
Cash And Short Term Investments2,7273,6074,381
Total Receivables, Net16,73317,65416,146
Total Inventory20,89018,23816,820
Prepaid expenses------
Other current assets, total1,1101,164562
Total current assets41,46040,66337,909
Property, plant & equipment, net31,97225,83723,116
Goodwill, net------
Intangibles, net490377386
Long term investments3,1882,9642,752
Note receivable - long term------
Other long term assets278207206
Total assets77,70870,55264,939
LIABILITIES
Accounts payable8,6998,1727,864
Accrued expenses1,0511,0911,170
Notes payable/short-term debt000
Current portion long-term debt/capital leases2,3741,4441,189
Other current liabilities, total6,3814,7213,846
Total current liabilities18,50515,42814,069
Total long term debt6,3453,4452,247
Total debt8,7194,8893,436
Deferred income tax323132
Minority interest196299367
Other liabilities, total561677917
Total liabilities25,63919,88017,632
SHAREHOLDERS EQUITY
Common stock7,1867,1867,031
Additional paid-in capital7,0727,0726,917
Retained earnings (accumulated deficit)37,08735,00632,345
Treasury stock - common(990)(124)(13)
Unrealized gain (loss)1,3321,159877
Other equity, total382373150
Total equity52,06950,67247,307
Total liabilities & shareholders' equity77,70870,55264,939
Total common shares outstanding151616
Treasury shares - common primary issue0.410.060.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.